Unresolved issues in lipid-lowering treatment

被引:0
|
作者
Tziomalos, Konstantinos [1 ]
机构
[1] Aristotle Univ Thessaloniki, Sch Med, Propedeut Dept Internal Med 1, AHEPA Hosp, Thessaloniki, Greece
关键词
Cardiovascular diseases; Cholesterol; LDL; HDL; Ezetimibe; PCSK9; protein; human; LOW-DENSITY-LIPOPROTEIN; TRANSFER PROTEIN-INHIBITION; INTENSIVE STATIN THERAPY; ISCHEMIC-HEART-DISEASE; VERY-LOW LEVELS; CARDIOVASCULAR EVENTS; CHOLESTEROL LEVELS; HDL CHOLESTEROL; HIGH-RISK; CORONARY-DISEASE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major modifiable risk factor for cardiovascular disease (CVD). In addition, treatment with statins reduces cardiovascular morbidity and mortality both in patients without and with established CVD. However, there still exist unresolved issues in the management of dyslipidemia. First, which are the optimal LDL-C levels? Second, do low high-density lipoprotein cholesterol (HDL-C) levels play a role in the pathogenesis of atherosclerosis and should they also represent treatment targets? In the present review, we discuss these two pertinent questions. Accumulating data, both from observational studies and from interventional studies with statins and other lipid lowering agents, suggest that lowering LDL-C levels considerably below the currently recommended targets is both safe and further reduces cardiovascular morbidity and mortality. These benefits are particularly relevant for patients at very high cardiovascular risk, i.e. those with established CVD. On the other hand, it is questionable whether HDL-C is causally related to atherosclerosis and whether increasing HDL-C levels will translate into reduced cardiovascular risk. This uncertainty is even more pronounced in patients who achieve very low LDL-C levels with statin treatment.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 50 条
  • [21] Lipid-lowering drugs
    K. Pahan
    Cellular and Molecular Life Sciences CMLS, 2006, 63 : 1165 - 1178
  • [22] LIPID-LOWERING DRUGS
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1980, 22 (16): : 65 - 66
  • [23] Lipid-Lowering Drugs
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1659): : 145 - +
  • [24] Lipid-Lowering Drugs
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1565): : 17 - 24
  • [25] A case for lipid-lowering?
    Durrington, P
    DIABETIC MEDICINE, 2000, 17 : 4 - 5
  • [26] Lipid-lowering and kidney
    Lee, Sang-Hak
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2023, 42 (04) : 412 - 414
  • [27] LIPID-LOWERING DRUGS
    THOMPSON, GR
    LANCET, 1988, 1 (8585): : 597 - 597
  • [28] Lipid-Lowering Agents
    Ewang-Emukowhate, Mfon
    Wierzbicki, Anthony S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 18 (05) : 401 - 411
  • [29] Lipid-lowering drugs
    Andréjak, M
    Caron, J
    Libersa, C
    Thery, C
    THERAPIE, 2003, 58 (01): : 1 - 2
  • [30] LIPID-LOWERING TREATMENTS
    DAIROU, F
    PRESSE MEDICALE, 1987, 16 (26): : 1277 - 1281